Making the Health Check work for you

Similar documents
Guidance on Risk Assessment and Stroke Prevention for Atrial Fibrillation (GRASP-AF) ALICE FOSTER HEAD PRESCRIBING ADVISER QIPP PRESCRIBING LEAD

GRASP-AF Audit Tool Instructional Guide

GRASP-AF Coming to a PCT near you.

NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation

Prevention of stroke in patients with atrial fibrillation

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

STROKE PREVENTION IN ATRIAL FIBRILLATION

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

Atrial Fibrillation An update on diagnosis and management

Costs and Benefits of Antithrombotic Therapy in Atrial Fibrillation in England: An Economic Analysis based on GRASP-AF

Anticoagulants in Atrial Fibrillation

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology

Dorset Cardiac Centre

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

Commissioning effective anticoagulation services for the future

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

National Medicines Information Centre

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE

Service Specification Template Department of Health, updated June 2015

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness SOGH April

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options?

NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)

4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285:

9/5/14. Objectives. Atrial Fibrillation (AF)

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

The Anti coagulated Patient: The Cardiologist s View. February 28, 2015

Management of Antithrombotics with Procedures. Jordan Weinstein, MD

All Wales Risk/Benefit Assessment Tool for Oral Anticoagulant Treatment in People with Atrial Fibrillation

Dabigatran in Atrial Fibrillation Question and Answers document to inform commissioners

NICE clinical guideline 180: Atrial fibrillation Prescribing and medicines optimisation issues

Anticoagulation Therapy Update

FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE

Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation.

Atrial fibrillation. Quick reference guide. Issue date: June The management of atrial fibrillation

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust

SUMMARY OF CHANGES TO QOF 2015/16 - ENGLAND CLINICAL

Stroke Prevention In Atrial Fibrillation Integrated Care Clinics Patient Reported Outcome Measures

Xarelto (Rivaroxaban)

Blood thinning (anticoagulation) in atrial fibrillation (AF)

Atrial Fibrillation: Stroke and Thromboprophylaxis. Derek Waller

Atrial Fibrillation Peter Santucci, MD Revised May, 2008

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY

How To Use Novel Anticoagulants In Cornwall

2015/16 General Medical Services (GMS) contract Quality and Outcomes Framework (QOF)

An Audit of the Documentation and Correct Referral of Patients on Initiation of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban)

Treatments to Restore Normal Rhythm

Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

Contents Chair s foreword... 5 Glossary of key terms... 7 The Committee s Key Conclusions and Recommendations... 8

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

On route to by optimising warfarin monitoring

Antiplatelet and Antithrombotics From clinical trials to guidelines

The debate: Should all AF patients see an EP consultant?

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

Survey of Canadian Physicians Use of anti-thrombotic therapy for Atrial Fibrillation

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE

CHA 2 DS 2 -VASc Score and Heart Rate Predict Ischemic Stroke Outcomes in Patients with Atrial Fibrillation

UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media

AHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

2014: nowadays the one shot technologies and the injectable monitor allow a wide and complete AF patient management. Why shouldn t we use them?

Breakfast symposium: From hospital to home - the focus on the patient

AF, Stroke Risk and New Anticoagulants

Updates to the Alberta Human Services Drug Benefit Supplement

How To Understand How The Brain Can Be Affected By Cardiac Problems

NIL. Dr Chuks Ajaero FMCP FRACP Cardiologist QEH, NALHN, SA Heart & Central Districts. Approach. Approach. 06-Nov-14

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

Stroke Prevention in Primary Care

rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (756/12) Bayer PLC

BRISTOL-MYERS SQUIBB and PFIZER/DIRECTOR v BAYER

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation

Framework guidance for GMS contract 2014/15. Contents

A PATIENT S GUIDE TO STROKE AND ATRIAL FIBRILLATION (AF)

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

One year on. Why are patients still having unnecessary AF-related strokes?

Best practice in the clinical management of atrial fibrillation in general practice

Updates to the Alberta Drug Benefit List. Effective January 1, 2016

Management of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39

Anticoagulation at the end of life. Rhona Maclean

TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

Atrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital

Leveraging EMR Data to Better Understand Local Market Potential and the Deployment of Commercial Resources

Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose. Warfarin vs the NOACs

Atrial Fibrillation Based on ESC Guidelines. Moshe Swissa MD Kaplan Medical Center

In this observational study, the effect of dabigatran and rivaroxaban on platelets will be evaluated.

AFib (short for atrial fibrillation) is the most common type of irregular heartbeat, affecting literally millions of men and women

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

The Unmet Need of Stroke Prevention in Atrial Fibrillation in the Far East and South East Asia

Xarelto (Atrial Fibrillation) - Analysis and Forecasts to 2022

The author has no disclosures

Transcription:

Making the Health Check work for you Atrial Fibrillation and the GRASP toolkit (Guidance on Risk Assessment and Stroke Prevention ) Dr. Indira Natarajan Consultant Stroke Physician University Hospital of North Staffordshire & Clinical lead for Stroke for the Heart and Stroke Network for Shropshire and Staffordshire

National Sentinel Audit Data

UHNS Acute Stroke Unit (ASU) 2001 2010 Outcome/ Result

One of the major risk factors for stroke Atrial fibrillation

Atrial fibrillation and Stroke 1200 Strokes / year at UHNS in 2011 15% of all Strokes are cardio embolic strokes secondary to AF AF Strokes lead to moderate and severe strokes AF still remains a treatable risk factor for preventing stroke

Atrial fibrillation facts. AF is the most common cardiac arrhythmia Prevalence of AF is increasing Risk of stroke persists in asymptomatic or paroxysmal AF DBG1778 Factors increasing stroke risk include: Previous stroke or transient ischaemic attack (TIA) Advancing age Heart failure Hypertension Diabetes mellitus Assessment of stroke risk is important to guide antithrombotic therapy

AF and associated stroke incur substantial healthcare costs 1 AF accounts for more than 1% of healthcare expenditure in the UK Total costs for treating the 12,500 strokes in England that are attributable to AF is 148 million in the first year DBG1778 The cost per stroke due to AF is estimated to be 11,900 in the first year after a stroke occurs Treating these patients with Warfarin could prevent 6,000 stokes nationally and save 4,000 lives each year (Nice 2006) 1. NHS Improvement. Commissioning for Stroke Prevention in Primary Care: The Role of Atrial Fibrillation. June 2009. Available at http://www.improvement.nhs.uk/heart/portals/0/ documents2009/af_commissioning_guide_v2.pdf; accessed April 2010

Risk Stratification Scores

Stroke severity increases costs Severe 4 5 34 809 Stroke severity* 3 2 12 323 18 281 DBG1778 0 1 10 530 Mild 0 5 10 15 20 25 30 35 40 Mean cost per patient over 18 months ( 1000) Data for 494 consecutive stroke patients in France; *10-day modified Rankin Scale Spieler JF et al. Cerebrovasc Dis 2002;13:132 41

AF and Stroke - An Audit 50 consecutive patients with AF 30 patients had moderate to severe strokes 9/ 50 were on warfarin ( 18%) 20/50 Known AF ( 40%) not on warfarin 32/50 (62%) Newly Diagnosed AF

GRASP AF Tool Kit Guidance on Risk Assessment and Stroke Prevention for Atrial Fibrillation

GRASP AF Tool The GRASP - AF tool will calculate their stroke risk using the validated CHADS2 scoring system this element of the toolkit now defaults to CHAD 2 S 2.VASc The tool will highlight patients with a CHADS2 score of 2 or more not receiving Warfarin who would benefit from review to assess the issue of anti-coagulation The tool does not assess contraindications to Warfarin, the decision whether or not to start Warfarin remains a clinical one

National direction The National aim is to support 2000 GP practices from across the UK to implement the GRASP Toolkit by the end of March 2012 The GRASP toolkit has been redesigned from using CHADS2 to default to CHAD 2 S 2.VASc Staffordshire Heart and Stroke Network aims to increase the number of practices using the GRASP toolkit within Shropshire and Staffordshire from 12% to 25% by the end of March 2012.

Uploading Data Quality Facilitators in each locality can upload GRASP AF Tool kit They can also help in uploading the data to CHART online so that we can benchmark local practice

Audit of Atrial Fibrillation and CHADS2 Scores Please click on the Web Upload icon to send in your data Classic View Select Risk Score Practice: Total Practice Population 5368 Total Percent No. with Atrial Fibrillation 95 1.77 Age >= 65 yrs with AF 77 6.17 Age range AF prevalence (%) by age band 0-29 30-49 50-64 65-74 75-84 85+ 0.0 5.0 10.0 15.0 Percentage 100 80 60 40 20 0 Risk profile for thrombo-embolism 0 1 >1 NB: Handling of anticoagulant exclusions AF prevalence (%) CHADS2 score Risk factors in patients with AF Breakdown of anticoagulant & antiplatelet use by CHADS score Heart Failure Hypertension Age >=75 Diabetes Stroke or TIA CHADS2 score 0 1 >1 1 7 2 2 0 2 2 9 2 22 39 7 Anticoagulant Both Antiplatelet None 0% 50% 100% 0% 20% 40% 60% 80% 100% Percentage Percentage 100 80 60 40 20 0 Anticoagulant use in high risk patients On anticoagulant (9 patients) Not on anticoagulant (48 patients) This dashboard w as developed by PRIMIS+ for use w ith CHART Strokes expected annually in the 48 high risk untreated 3.2 (95% CI 2.4 to 4.2) Percentage 100 80 60 40 20 0 Score or review in last 15 mths CHADS2 AF review HELP OVERVIEW PODCAST PRIMIS+ 2011

Audit of Atrial Fibrillation and CHA2DS2-VASc Scores Please click on the Web Upload icon to send in your data Classic View Select Risk Score Practice: Total Practice Population 5368 Total Percent No. with Atrial Fibrillation 95 1.77 Age >= 65 yrs with AF 77 6.17 Age range AF prevalence (%) by age band 0-29 30-49 50-64 65-74 75-84 85+ 0.0 5.0 10.0 15.0 Percentage 100 80 60 40 20 0 Risk profile for thrombo-embolism 0 1 >1 NB: Handling of anticoagulant exclusions AF prevalence (%) CHA2DS2-VASc score Risk factors in patients with AF Breakdown of anticoagulant & antiplatelet use by CHA2DS2-VASc score HF or LVD Hypertension Age >=75 Diabetes Stroke or TIA Vasc disease Age 65-74 CHA2DS2-VASc score 0 1 >1 1 1 8 3 1 9 2 1 1 61 5 2 Anticoagulant Both Antiplat elet None Sex = Female 0% 20% 40% 60% 80% 100% 0% 50% 100% Percentage Percentage 100 80 60 40 20 0 Anticoagulant use in high risk patients On anticoagulant (11 patients) Not on anticoagulant (70 patients) This dashboard w as developed by PRIMIS+ for use w ith CHART Strokes expected annually in the 70 high risk untreated 3.5 Percentage 100 80 60 40 20 0 Score or review in last 15 mths CHADS2 AF review HELP OVERVIEW PODCAST PRIMIS+ 2011

So far. 1350 out of 8000 GP practices across the UK are using the toolkit, the aim is to encourage 2000 GP practices to implement the GRASP toolkit by the end of March 2012

Locally. 12% of GP practices across Shropshire and Staffordshire are using GRASP the toolkit at present, this was confirmed by the National team in December 2011 predominately these are within North Staffordshire

AF Stroke Strategy Locally we have helped in developing a network wide AF Strategy for both : Primary Care and Secondary Care The use of GRASP tool kit within North Staffs PCT - more people with AF are now taking anticoagulants therefore, prevention of strokes have occurred.

Regional Commissioning Framework One of the key ambitions is to improve quality and safety in primary care SHA Cluster Board have agreed 4 key objectives and one of the key objectives: Is to Improve management of patients taking warfarin by uploading the GRASP tool KIT this objective can be achieved

Developments Meetings are being arranged with CCG Chairs/Managers to discuss the implementation of the GRASP toolkit Atrial Fibrillation training days have taken place in June and November 2011 working with Staffordshire University. Further developments expected regarding the new anticoagulants Numbers of GP practices across the network using the GRASP toolkit have been identified by linking with the national team Links have been made with Data Quality Facilitators across the network to assist with implementation PRIMIS has been contacted to include AF within its web page, this has been achieved, CHART online now demonstrates AF Personally championing the need for Stroke Prevention secondary to AF

In Summary. The Shropshire and Staffordshire Heart and Stroke Network aims to increase the number of practices using the GRASP toolkit within Shropshire and Staffordshire from 12% to 25% by the end of March 2012. This will be achieved by working closely with the new GP Commissioning Consortia and promoting the adoption of the system at GP protected learning time events, training opportunities provided by the network focusing on Atrial Fibrillation and sharing national information from the NHS Improvement team with GP s across the network. Awareness raising will increase the uptake of the system and should increase the anticipation of reaching a target of 25% of all GP practices across Shropshire and Staffordshire using the GRASP toolkit.

Thank You